Abstract:This article explores the synthesis, characterization, and molecular docking of novel coumarin analogs. The results demonstrate their antidiabetic potential, evidenced by reductions in blood glucose levels and HbA1c after four weeks of treatment. Additionally, low levels of SGOT and SGPT suggest hepatoprotective properties. Histological analysis confirms that the synthesized compounds exhibit no signs of toxicity in the liver and kidneys. Diabetes and its associated conditions are significant causes of morbidity and mortality. Despite the abundance of available medications for diabetes treatment, their limitations have spurred ongoing research in this field. Consequently, there is a need to discover a potential therapeutic molecule for managing diabetes and its complications. In current research work a series of novel coumarin analogs (5a–5e) were designed, synthesized, characterized through FTIR, 1H NMR, 13C NMR, and mass spectroscopy and evaluated for antidiabetic property. Molecular docking study was performed to link its binding affinity toward AMPK. DPPH scavenging assay was performed for in vitro antioxidant activity, for reference standard ascorbic acid was taken. In vivo hypoglycemic activity was performed on streptozotocin and nicotinic acid induced diabetic rats. All synthesized molecule showed good docking, score among them compound 5b has lowest docking score −11.25 kcal/mol. Molecule 5b and 5c showed greater antioxidant potential with good IC50 value, i.e., 20.4 g/mL and 21.6 g/mL. In vivo antidiabetic study showed good control on blood glucose level, cholesterol, triglyceride, Hb1AC as well as SGOT and SGPT level on animals fed 5b when compared to metformin. This result showed that test molecule 5b has potential to lower the blood glucose level without causing any toxicity.

Synthesis of Novel Curcumin Analogues for Inhibition of 11Β-Hydroxysteroid Dehydrogenase Type 1 with Anti-Diabetic Properties

Mono-carbonyl Curcumin Analogues As 11Β-Hydroxysteroid Dehydrogenase 1 Inhibitors.

Curcumin As A Potent And Selective Inhibitor Of 11 Beta-Hydroxysteroid Dehydrogenase 1: Improving Lipid Profiles In High-Fat-Diet-Treated Rats

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

The 11Β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Protects Against the Insulin Resistance and Hepatic Steatosis in Db/db Mice.

Design, Synthesis, and Biological Evaluation of 1,4-Diaryl-1,4-dihydropyrazines As Novel 11Β-Hsd1 Inhibitors.

Discovery of Novel Sulfonamides As Potent and Selective Inhibitors Against Human and Mouse 11Β-Hydroxysteroid Dehydrogenase Type 1

Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.

Progress in 11Β-Hsd1 Inhibitors for the Treatment of Metabolic Diseases: A Comprehensive Guide to Their Chemical Structure Diversity in Drug Development.

Efficacious 11Beta-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model.

Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344)

Synthesis of potent and orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016.

Citrinal B, natural 11 beta-hydroxysteroid dehydrogennase type 1 inhibitor identified from structure-based virtual screening.

Potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 labeled with carbon-13 and carbon-14.

Synthesis and Biological Activity of trans-Tiliroside Derivatives as Potent Anti-Diabetic Agents

Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.

Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes

Discovery Of 2-Alkyl-1-Arylsulfonylprolinamides As 11 Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors

Design, Synthesis, Molecular Docking and Hypoglycemic Activity of Novel Coumarin Analogues

Demethoxylation of Curcumin Enhances Its Inhibition on Human and Rat 178-Hydroxysteroid Dehydrogenase 3: QSAR Structure-Activity Relationship and in Silico Docking Analysis

Demethoxylation of curcumin enhances its inhibition on human and rat 17β-hydroxysteroid dehydrogenase 3: QSAR structure-activity relationship and in silico docking analysis